Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Strand

Showing results (101-110 of 150) with videos related to

Pageof 15
Sort By:
Arthritis and Rheumatism|March 13, 2003
An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trialT Pincus, V Strand, G Koch, et al.
Arthritis Care & Research|August 28, 2010
American College of Rheumatology hybrid analysis of certolizumab pegol plus methotrexate in patients with active rheumatoid arthritis: data from a 52-week phase III trialR F van Vollenhoven, D Felson, V Strand, et al.
Arthritis and Rheumatism|October 8, 1999
Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators GroupV Strand, P Tugwell, C Bombardier, et al.
The Journal of Rheumatology|January 26, 1999
Patient based methods for assessing adverse events in clinical trials in rheumatology. Progress report for the OMERACT Drug Toxicity Working Party. Outcome Measures in RheumatologyM Gazarian, P Tugwell, M Boers, et al.
Arthritis and Rheumatism|March 23, 2000
Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigators GroupP Tugwell, G Wells, V Strand, et al.
Respiratory Medicine|November 7, 2002
Ambient level of NO2 augments the inflammatory response to inhaled allergen in asthmaticsC Barck, T Sandström, J Lundahl, et al.
The Journal of Rheumatology|March 15, 2001
Minimal clinically important differences: review of methodsG Wells, D Beaton, B Shea, et al.
European Journal of Oral Sciences|July 21, 2019
Randomized controlled trial of the effectiveness of three different oral moisturizers in palliative care patientsSiri F Kvalheim, Mihaela C Marthinussen, Dagny F Haugen, et al.
The Journal of Rheumatology|April 27, 2000
A proposal for developing a large patient population cohort for longterm safety monitoring in rheumatoid arthritisJ A Lipani, V Strand, T Woodworth, et al.
Annals of the Rheumatic Diseases|February 14, 2012
A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexateP Mease, V Strand, L Shalamberidze, et al.
Pageof 15

Showing results (101-110 of 150) with videos related to

Sort By:
Pageof 15
Arthritis and Rheumatism|March 13, 2003
An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trialT Pincus, V Strand, G Koch, et al.
Arthritis Care & Research|August 28, 2010
American College of Rheumatology hybrid analysis of certolizumab pegol plus methotrexate in patients with active rheumatoid arthritis: data from a 52-week phase III trialR F van Vollenhoven, D Felson, V Strand, et al.
Arthritis and Rheumatism|October 8, 1999
Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators GroupV Strand, P Tugwell, C Bombardier, et al.
The Journal of Rheumatology|January 26, 1999
Patient based methods for assessing adverse events in clinical trials in rheumatology. Progress report for the OMERACT Drug Toxicity Working Party. Outcome Measures in RheumatologyM Gazarian, P Tugwell, M Boers, et al.
Arthritis and Rheumatism|March 23, 2000
Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigators GroupP Tugwell, G Wells, V Strand, et al.
Respiratory Medicine|November 7, 2002
Ambient level of NO2 augments the inflammatory response to inhaled allergen in asthmaticsC Barck, T Sandström, J Lundahl, et al.
The Journal of Rheumatology|March 15, 2001
Minimal clinically important differences: review of methodsG Wells, D Beaton, B Shea, et al.
European Journal of Oral Sciences|July 21, 2019
Randomized controlled trial of the effectiveness of three different oral moisturizers in palliative care patientsSiri F Kvalheim, Mihaela C Marthinussen, Dagny F Haugen, et al.
The Journal of Rheumatology|April 27, 2000
A proposal for developing a large patient population cohort for longterm safety monitoring in rheumatoid arthritisJ A Lipani, V Strand, T Woodworth, et al.
Annals of the Rheumatic Diseases|February 14, 2012
A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexateP Mease, V Strand, L Shalamberidze, et al.
Pageof 15